| Investor | Avidity Partners Management LP |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Avidity Partners Management LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | 13G/A | CNTX / Context Therapeutics Inc. | 9,200,580 | 8,302,808 | ||||
| 2026-04-17 | 13G | IMUX / Immunic, Inc. | 4,699,411 | 13,958,410 | ||||
| 2026-03-10 | 13G | CATX / Perspective Therapeutics, Inc. | 2,841,024 | 6,049,999 | ||||
| 2026-02-17 | 13G/A | SCYX / SCYNEXIS, Inc. | 4,516,757 | 4,426,565 | ||||
| 2025-11-19 | 13D/A | DNTH / Dianthus Therapeutics, Inc. | 3,378,939 | 2,104,184 | ||||
| 2025-11-14 | 13G/A | CNTX / Context Therapeutics Inc. | 9,126,176 | 9,200,580 | ||||
| 2025-11-14 | 13G/A | SCYX / SCYNEXIS, Inc. | 4,211,870 | 4,516,757 | ||||
| 2025-11-14 | 13G/A | IMUX / Immunic, Inc. | 5,615,811 | 4,699,411 | ||||
| 2025-11-14 | 13G/A | KZR / Kezar Life Sciences, Inc. | 0 | |||||
| 2025-08-14 | 13G/A | IMUX / Immunic, Inc. | 6,041,059 | 5,615,811 | ||||
| 2025-08-14 | 13G/A | CNTX / Context Therapeutics Inc. | 7,776,296 | 9,126,176 | ||||
| 2025-05-15 | 13G/A | IMUX / Immunic, Inc. | 9,022,363 | 6,041,059 | ||||
| 2025-03-19 | 13D/A | DNTH / Dianthus Therapeutics, Inc. | 2,930,250 | 3,378,939 | ||||
| 2025-02-14 | 13G/A | KZR / Kezar Life Sciences, Inc. | 5,025,454 | |||||
| 2025-02-14 | 13G/A | CATX / Perspective Therapeutics, Inc. | 3,590,426 | 2,841,024 | ||||
| 2025-02-14 | 13G/A | SCYX / SCYNEXIS, Inc. | 4,177,203 | 4,211,870 | ||||
| 2025-02-14 | 13G/A | IMUX / Immunic, Inc. | 8,989,443 | 9,022,363 | ||||
| 2025-02-14 | 13G/A | SYRS / Syros Pharmaceuticals, Inc. | 2,857,573 | 2,048,020 | ||||
| 2025-02-14 | 13G/A | CNTX / Context Therapeutics Inc. | 7,776,296 | 7,776,296 | ||||
| 2024-12-03 | 13D/A | DNTH / Dianthus Therapeutics, Inc. | 2,922,823 | 2,930,250 | ||||
| 2024-11-14 | 13G/A | ORKA / Oruka Therapeutics, Inc. | 790,926 | |||||
| 2024-11-14 | 13G/A | SCYX / SCYNEXIS, Inc. | 4,105,210 | 4,177,203 | ||||
| 2024-11-14 | 13G | CATX / Perspective Therapeutics, Inc. | 3,590,426 | |||||
| 2024-11-14 | 13G/A | CRBU / Caribou Biosciences, Inc. | 6,360,212 | 0 | ||||
| 2024-11-14 | 13G/A | JSPR / Jasper Therapeutics, Inc. | 760,000 | 0 | ||||
| 2024-11-14 | 13G/A | IMUX / Immunic, Inc. | 8,899,418 | 8,989,443 | ||||
| 2024-11-14 | 13G/A | CNTX / Context Therapeutics Inc. | 7,776,296 | 7,776,296 | ||||
| 2024-11-14 | 13G/A | SYRS / Syros Pharmaceuticals, Inc. | 2,662,206 | 2,857,573 | ||||
| 2024-11-14 | 13G/A | KPTI / Karyopharm Therapeutics Inc. | 11,188,743 | 4,741,060 | ||||
| 2024-05-13 | 13G | CNTX / Context Therapeutics Inc. | 7,776,296 | |||||
| 2024-04-09 | 13G | ABIO / ARCA biopharma, Inc. | 1,000,000 | |||||
| 2024-03-27 | 13G | JSPR / Jasper Therapeutics, Inc. | 760,000 | |||||
| 2024-02-14 | 13G/A | ALT / Altimmune, Inc. | 3,990,000 | 0 | ||||
| 2024-02-14 | 13G/A | KZR / Kezar Life Sciences, Inc. | 6,782,400 | 5,025,454 | ||||
| 2024-02-14 | 13G/A | IDYA / IDEAYA Biosciences, Inc. | 3,824,800 | 1,520,000 | ||||
| 2024-02-14 | 13G/A | KPTI / Karyopharm Therapeutics Inc. | 11,381,073 | 11,188,743 | ||||
| 2024-02-13 | 13G/A | CYTT / Cyteir Therapeutics, Inc. | 1,795,800 | 0 | ||||
| 2024-02-13 | 13G/A | PRTA / Prothena Corporation plc | 2,953,000 | 0 | ||||
| 2024-02-13 | 13G/A | SCYX / SCYNEXIS, Inc. | 3,624,523 | 4,105,210 | ||||
| 2024-02-13 | 13G/A | AKRO / Akero Therapeutics, Inc. | 3,825,000 | 235,000 | ||||
| 2024-02-13 | 13G/A | ZNTL / Zentalis Pharmaceuticals, Inc. | 5,150,000 | 0 | ||||
| 2024-02-13 | 13G/A | SYRS / Syros Pharmaceuticals, Inc. | 2,189,719 | 2,662,206 | ||||
| 2024-02-13 | 13G/A | ARVN / Arvinas, Inc. | 4,950,000 | 2,985,117 | ||||
| 2024-02-13 | 13G/A | ARVN / Arvinas, Inc. | 4,950,000 | 2,985,117 | ||||
| 2024-02-13 | 13G/A | NSTGQ / NS Wind Down Co., Inc. | 2,950,000 | 0 | ||||
| 2024-02-13 | 13G/A | SNDX / Syndax Pharmaceuticals, Inc. | 6,718,142 | 3,950,000 | ||||
| 2024-02-13 | 13G/A | FUSN / Fusion Pharmaceuticals Inc. | 6,824,450 | 6,500,328 | ||||
| 2024-02-13 | 13G/A | PRAX / Praxis Precision Medicines, Inc. | 4,100,000 | 0 | ||||
| 2024-01-31 | 13D | DNTH / Dianthus Therapeutics, Inc. | 2,922,823 | |||||
| 2024-01-16 | 13G | IMUX / Immunic, Inc. | 8,899,418 | |||||
| 2024-01-08 | 13G | CRBU / Caribou Biosciences, Inc. | 6,360,212 | |||||
| 2023-10-23 | 13G | FUSN / Fusion Pharmaceuticals Inc. | 6,824,450 | |||||
| 2023-05-25 | 13G | NSTGQ / NS Wind Down Co., Inc. | 2,950,000 | |||||
| 2023-02-14 | 13G/A | PRTA / Prothena Corporation plc | 2,953,000 | |||||
| 2023-02-14 | 13G/A | SYRS / Syros Pharmaceuticals, Inc. | 2,120,000 | 2,189,719 | ||||
| 2023-02-14 | 13G/A | SCYX / SCYNEXIS, Inc. | 2,239,278 | 3,624,523 | ||||
| 2023-02-14 | 13G/A | EPIX / ESSA Pharma Inc. | 3,750,000 | 1,855,400 | ||||
| 2023-02-14 | 13G/A | ALT / Altimmune, Inc. | 2,765,000 | 3,990,000 | ||||
| 2023-02-14 | 13G/A | SNDX / Syndax Pharmaceuticals, Inc. | 5,244,019 | 6,718,142 | ||||
| 2023-02-14 | 13G/A | KZR / Kezar Life Sciences, Inc. | 3,228,200 | 6,782,400 | ||||
| 2023-02-14 | 13G/A | IDYA / IDEAYA Biosciences, Inc. | 2,553,000 | 3,824,800 | ||||
| 2023-02-14 | 13G/A | ALPN / Alpine Immune Sciences, Inc. | 2,205,687 | 1,888,887 | ||||
| 2023-02-14 | 13G/A | KPTI / Karyopharm Therapeutics Inc. | 11,351,819 | 11,381,073 | ||||
| 2023-02-14 | 13G/A | GRTS / Gritstone bio, Inc. | 6,990,194 | 2,859,971 | ||||
| 2023-02-14 | 13G/A | AKRO / Akero Therapeutics, Inc. | 3,105,000 | 3,825,000 | ||||
| 2023-02-14 | 13G/A | CYTT / Cyteir Therapeutics, Inc. | 1,849,538 | 1,795,800 | ||||
| 2023-02-14 | 13G/A | PHASQ / PhaseBio Pharmaceuticals, Inc. | 4,405,000 | 2,040,000 | ||||
| 2023-02-14 | 13G/A | PHAT / Phathom Pharmaceuticals, Inc. | 1,896,000 | 1,900,000 | ||||
| 2023-02-14 | 13G/A | ARVN / Arvinas, Inc. | 3,239,838 | 4,950,000 | ||||
| 2023-02-14 | 13G/A | ISEE / IVERIC bio Inc | 6,955,000 | 838,407 | ||||
| 2023-02-14 | 13G/A | US68234L4059 / ONCOSEC MEDICAL INC | 0 | |||||
| 2023-02-14 | 13G/A | ACET / Adicet Bio, Inc. | 3,034,004 | 0 | ||||
| 2023-02-14 | 13G/A | VRDN / Viridian Therapeutics, Inc. | 1,278,261 | 0 | ||||
| 2023-02-14 | 13G/A | ZNTL / Zentalis Pharmaceuticals, Inc. | 3,022,790 | 5,150,000 | ||||
| 2023-02-02 | 13G | PRAX / Praxis Precision Medicines, Inc. | 4,100,000 | |||||
| 2022-12-08 | 13G | KPTI / Karyopharm Therapeutics Inc. | 11,351,819 | |||||
| 2022-10-27 | 13G | EPIX / ESSA Pharma Inc. | 3,750,000 | |||||
| 2022-09-20 | 13G | SYRS / Syros Pharmaceuticals, Inc. | 2,120,000 | |||||
| 2022-09-16 | 13G | AKRO / Akero Therapeutics, Inc. | 3,105,000 | |||||
| 2022-06-16 | 13G | ARVN / Arvinas, Inc. | 3,239,838 | |||||
| 2022-02-14 | 13G/A | IDYA / IDEAYA Biosciences, Inc. | 2,470,179 | 2,553,000 | ||||
| 2022-02-14 | 13G/A | SCYX / SCYNEXIS, Inc. | 1,979,800 | 2,239,278 | ||||
| 2022-02-14 | 13G/A | SNDX / Syndax Pharmaceuticals, Inc. | 4,750,000 | 5,244,019 | ||||
| 2022-02-14 | 13G | SPNE / SeaSpine Holdings Corp | 2,010,000 | 2,010,000 | ||||
| 2022-02-14 | 13G/A | CRDF / Cardiff Oncology, Inc. | 2,153,600 | 0 | ||||
| 2022-02-14 | 13G/A | GRTS / Gritstone bio, Inc. | 4,546,814 | 6,990,194 | ||||
| 2022-02-14 | 13G/A | ALPN / Alpine Immune Sciences, Inc. | 1,470,390 | 2,205,687 | ||||
| 2022-02-14 | 13G/A | ONCS / OncoSec Medical Inc | 1,952,000 | 2,945,000 | ||||
| 2022-02-14 | 13G/A | ANIK / Anika Therapeutics, Inc. | 731,000 | 0 | ||||
| 2022-02-14 | 13G | CYT / Cyteir Therapeutics, Inc. | 1,849,538 | 1,849,538 | ||||
| 2022-02-14 | 13G | PHAT / Phathom Pharmaceuticals, Inc. | 1,896,000 | 1,896,000 | ||||
| 2022-02-14 | 13G/A | ACET / Adicet Bio, Inc. | 1,860,000 | 3,034,004 | ||||
| 2022-02-14 | 13G/A | ISEE / IVERIC bio Inc | 7,225,000 | 6,955,000 | ||||
| 2022-02-14 | 13G/A | PHAS / PhaseBio Pharmaceuticals Inc | 4,285,000 | 4,405,000 | ||||
| 2022-02-14 | 13G/A | VRDN / Viridian Therapeutics, Inc. | 1,120,925 | 1,278,261 | ||||
| 2022-02-01 | 13G | ZNTL / Zentalis Pharmaceuticals, Inc. | 3,022,790 | |||||
| 2022-01-03 | 13G | KZR / Kezar Life Sciences, Inc. | 3,228,200 | |||||
| 2022-01-03 | 13G | ALT / Altimmune, Inc. | 2,765,000 | |||||
| 2021-12-01 | 13G | IDYA / IDEAYA Biosciences, Inc. | 2,470,179 | |||||
| 2021-10-28 | 13G | VRDN / Viridian Therapeutics, Inc. | 1,120,925 | 1,120,925 | ||||
| 2021-10-25 | 13G | ISEE / IVERIC bio Inc | 7,225,000 | |||||
| 2021-04-20 | 13G/A | SNDX / Syndax Pharmaceuticals, Inc. | 3,308,000 | 4,750,000 | ||||
| 2021-03-22 | 13G | PHAS / PhaseBio Pharmaceuticals Inc | 4,285,000 | |||||
| 2021-02-16 | 13G/A | ONCS / OncoSec Medical Inc | 1,690,000 | 1,952,000 | ||||
| 2021-02-16 | 13G/A | ALPN / Alpine Immune Sciences, Inc. | 1,337,413 | 1,470,390 | ||||
| 2021-02-16 | 13G | ANIK / Anika Therapeutics, Inc. | 731,000 | |||||
| 2021-02-16 | 13G/A | SCYX / SCYNEXIS, Inc. | 1,097,254 | 1,979,800 | ||||
| 2021-02-16 | 13G/A | SNDX / Syndax Pharmaceuticals, Inc. | 2,600,000 | 3,308,000 | ||||
| 2021-02-16 | 13G | KDMN / Kadmon Holdings Inc | 9,570,000 | |||||
| 2021-02-12 | 13G | ACET / Adicet Bio, Inc. | 1,860,000 | |||||
| 2021-02-02 | 13G | CRDF / Cardiff Oncology, Inc. | 2,153,600 | 2,153,600 | ||||
| 2021-02-02 | 13G | CRDF / Cardiff Oncology, Inc. | 2,153,600 | 2,153,600 | ||||
| 2020-12-30 | 13G | ONCS / OncoSec Medical Inc | 1,690,000 | |||||
| 2020-12-28 | 13G | GRTS / Gritstone bio, Inc. | 4,546,814 | |||||
| 2020-12-23 | 13G | SCYX / SCYNEXIS, Inc. | 1,097,254 | |||||
| 2020-12-23 | 13G | ALPN / Alpine Immune Sciences, Inc. | 1,337,413 | |||||
| 2020-11-04 | 13G | SNDX / Syndax Pharmaceuticals, Inc. | 2,600,000 | |||||
| 2020-03-12 | 13G | 867328601 / Sunesis Pharmaceuticals, Inc. | 4,951,925 | 4,951,925 | ||||
| 2020-03-11 | 13G | 867328601 / Sunesis Pharmaceuticals, Inc. | 4,951,925 |
